269
Views
7
CrossRef citations to date
0
Altmetric
Case Reports

A case of dermatomyositis with rhabdomyolysis, rescued by intravenous immunoglobulin

, , , , &
Pages 646-648 | Received 12 Feb 2013, Accepted 05 Jun 2013, Published online: 05 Nov 2013
 

Abstract

We describe a case of severe dermatomyositis (DM) complicated by rhabdomyolysis, acute tubular necrosis, and hemophagocytosis. The case failed to respond to corticosteroids, but showed rapid and significant improvement after the addition of intravenous immunoglobulin (IVIG). While the prognosis of DM is poor when it is complicated by rhabdomyolysis, the early administration of IVIG has the potential to be the cornerstone of its management.

Acknowledgements

We thank Masaki Takayanagi at Ciba Children's Hospital for analyzing CPTII activity, Yosuke Shigematsu at Fukui University for serum acylcarnitine analysis, and Tetsuhiko Yasuno at Fukuoka University for gene analysis.

Conflict of interest

H.K. has served as a consultant to Chugai Pharmaceutical and has received research grants from Eisai Pharmaceutical and Takeda Pharmaceutical. N.M. has received research grants from Abbott, Astellas Pharmaceutical, Banyu Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo Pharmaceutical, Eisai Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical and Teijin Pharmaceutical. All other authors have declared no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.